Intra-Cellular Therapies (NASDAQ:ITCI) Stock Rating Lowered by Leerink Partnrs

Leerink Partnrs lowered shares of Intra-Cellular Therapies (NASDAQ:ITCI) from a strong-buy rating to a hold rating in a report issued on Monday,Zacks.com reports.

Several other equities analysts also recently weighed in on ITCI. Royal Bank of Canada increased their price target on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday. JPMorgan Chase & Co. raised their target price on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a report on Monday, November 4th. Needham & Company LLC reaffirmed a “hold” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a report on Monday. Finally, Morgan Stanley increased their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Six investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Intra-Cellular Therapies currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.31.

Intra-Cellular Therapies Trading Down 0.2 %

NASDAQ:ITCI opened at $126.89 on Monday. The company has a market capitalization of $13.45 billion, a P/E ratio of -145.85 and a beta of 0.70. Intra-Cellular Therapies has a 12 month low of $62.78 and a 12 month high of $128.00. The firm has a fifty day simple moving average of $87.14 and a 200-day simple moving average of $79.68.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The firm had revenue of $175.40 million for the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business’s revenue was up 39.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.25) EPS. Equities analysts forecast that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Insider Activity at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, President Michael Halstead sold 22,869 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Intra-Cellular Therapies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $32,000. GAMMA Investing LLC lifted its stake in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 240 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in Intra-Cellular Therapies in the 3rd quarter worth about $74,000. Wilmington Savings Fund Society FSB purchased a new stake in Intra-Cellular Therapies during the 3rd quarter worth approximately $97,000. Finally, Quarry LP raised its holdings in shares of Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 1,300 shares during the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.